Paul N. Lucas

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

Luminex Molecular Diagnostics, Inc. develops DNA based diagnostics tests and software solutions, which include genetic tests for disorders, drug metabolism and infectious diseases. The firm’s products include P450-2D6, P450-2C9, P450-2C19, AJ panel and CFTR. The company was founded in March 2007 and is headquartered in Toronto, Canada.

Select Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is focused on the development of cell based therapeutics production. The company was founded by Clifford A. Lingwood in January 1997 and is headquartered in Brookline, MA.

Innovative Medicines Canada manufactures medical and toilet products. The company was founded on April 23, 1914 and is headquartered in Ottawa, Canada.

Part of Eli Lilly & Co., Eli Lilly Canada, Inc. is a healthcare leader that focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. The private company is based in Scarborough, Canada. Established in 1938, the Canadian company collaborates with scientists to produce innovative medicines that make life better for people around the world. The company's mission is to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to communities through philanthropy and volunteerism.

Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.